anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Image

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 119,566
Current window 89,461-89,490
Pages 3,986
Rows per page 30
Component: Imageclear collectionreset all
18 30 60

Component

89,461-89,490 of 119,566

filter-aware
21
Part of a Q3 2023 revenue presentation.LVMH | Results Presentation Deck | 29 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
24
This appears to be a placeholder or transition slide in a presentation deck, using a Louis Vuitton brand image.LVMH | Results Presentation Deck | 29 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
26
The slide uses a high-fashion photography aesthetic typical of luxury brand presentations.LVMH | Results Presentation Deck | 29 slides · LVMH
Conference presentation Investor relations 1 hit
01
Slide 1
The background image depicts chromosomes, reinforcing the telomere-targeting focus.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
02
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
03
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style layout to map drug candidates against clinical development stages.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Problem1 hit
08
The slide uses a three-column layout with circular callouts to present demographic and health statistics.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
09
This slide serves as a transition or key message reinforcement.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
11
Slide highlights a strategic partnership/supply agreement as a form of business traction.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
22
The slide shows a biological mechanism of action (MOA) validation using a dot plot to show TIFs increase over 72 hours.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
32
The slide highlights both regulatory NCE exclusivity and a specific count of issued/pending patents.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
35
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
36
The chart compares the $42B combined market of major CPIs against a $0.5B figure, likely representing the company's specific asset or segment.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
01
Slide 1
Mainz Biomed NV | Investor Presentation Deck | 27 slidesMainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
02
Mainz Biomed NV | Investor Presentation Deck | 27 slidesMainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
01
Slide 1
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
02
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
The slide presents clinical validation data for the ColoAlert diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
10
The slide features a minimalist design with a corporate logo and a halftone dot pattern.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
Uses a visual timeline/process flow to explain the disease progression.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
15
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
24
The slide uses a grid layout to present 10 key advisors with headshots, titles, and company logos.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
25
The slide uses a DNA double-helix motif to represent the company's focus on molecular diagnostics.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
27
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
28
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit